Announcement
20.02.2012


At the company's Extraordinary General Meeting today, the following issues were
adopted by the general meeting:

1. A reduction of the company's share capital by DKK 466,524,993 from DKK
491,078,940 to DKK 24,553,947 by transfer to a special reserve and
reduction of the nominal value of the company's shares from DKK 1 to DKK
0.05, and to amend Articles 3 and 13 of the Articles of Association
accordingly.
2. An amendment of Articles 4, 4d, 4e, 4f and 4g of the Articles of
Association as a consequence of the proposal under item 1 to reduce the
nominal value of the company's shares from DKK 1 to DKK 0.05.

Patrik Dahlen
CEO


Contact persons:
Patrik Dahlen, CEO, telephone: +45 4460 8214 or +45 2629 7296
René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097


About NeuroSearch
NeuroSearch A/S (NEUR) is a European-based biopharmaceutical company listed on
NASDAQ OMX Copenhagen A/S and specialising in central nervous system (CNS)
disorders. The vision is to develop NeuroSearch into a profitable specialty
pharmaceutical company. The strategy is to complete the development and
subsequently to market Huntexil®, a unique drug in clinical Phase III for the
treatment of the motor symptoms of Huntington’s disease.
As a consequence of the restructuring of NeuroSearch that was announced 27
September 2011, the company also has a portfolio of assets for outlicensing or
divestment.

Fonds.04-12 - Result of EGM - uk.pdf